| Fiellin, David |
NCT06323824: Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment. |
|
|
| Recruiting | 4 | 600 | US | Methadone, Buprenorphine (BUP) | Yale University, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), The Emmes Company, LLC, University of California, San Francisco, Boston Medical Center (BMC), Hennepin Healthcare Research Institute, Alameda Health System, Marshall Health, Kaiser Permanente | Opioid Use Disorder | 12/28 | 05/29 | | |
NCT04225598: Emergency Department-Initiated Buprenorphine Validation Network Trial |
|
|
| Completed | 2 | 2000 | US | CAM2038, Buprenorphine Sublingual Product | Yale University, National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, Harvard Medical School (HMS and HSDM), University of Pennsylvania, NYU Langone Health, Icahn School of Medicine at Mount Sinai, Alameda Health System, Weill Medical College of Cornell University, National Institute on Drug Abuse (NIDA) | Opioid-use Disorder | 12/24 | 12/24 | | |
NCT04793685: Prazosin for Alcohol Use Disorder With Withdrawal Symptoms |
|
|
| Recruiting | 1/2 | 150 | US | Prazosin, Minipress, 12-Step Facilitation with Relapse Prevention and Contingency Management | Yale University | Alcohol Withdrawal | 06/26 | 06/27 | | |
NCT02907944: Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation |
|
|
| Completed | N/A | 3838 | US | Implementation Facilitation | Yale University, National Institute on Drug Abuse (NIDA) | Substance-related Disorders | 09/21 | 09/21 | | |
| Completed | N/A | 120 | US | Contingency Management Counseling, Addiction Physician Management, Motivational Enhancement Therapy | Yale University, VA Connecticut Healthcare System, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Unhealthy Alcohol Use | 04/23 | 04/23 | | |
| Sinha, Rajita |
NCT03980184: Guanfacine to Improve Substance Use Outcomes in Women |
|
|
| Completed | 2 | 74 | US | Guanfacine, Tenex,, Behavioral Counseling, Manualized Drug Counseling | Yale University, National Institute on Drug Abuse (NIDA) | Substance Use Disorders | 11/22 | 11/22 | | |
SICA 2, NCT05322941: Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD) |
|
|
| Completed | 2 | 333 | US | AEF0117, 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one, Placebo oral capsule, Placebo | Aelis Farma, National Institute on Drug Abuse (NIDA) | Marijuana Abuse | 04/24 | 07/24 | | |
NCT05781009: Pregnenolone for the Treatment of Alcohol Use Disorder |
|
|
| Recruiting | 2 | 150 | US | Pregnenolone, Placebo | Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 07/28 | 07/28 | | |
NCT04793685: Prazosin for Alcohol Use Disorder With Withdrawal Symptoms |
|
|
| Recruiting | 1/2 | 150 | US | Prazosin, Minipress, 12-Step Facilitation with Relapse Prevention and Contingency Management | Yale University | Alcohol Withdrawal | 06/26 | 06/27 | | |
NCT04226690: Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products |
|
|
| Completed | 1 | 24 | US | Active CBD/THC Dose 1, Medical marijuana medicine, Active CBD/THC Dose 2, matched placebo comparator, Placebo | Yale University, Connecticut Pharmaceutical Solutions | Pain | 12/23 | 12/23 | | |
NCT05447286: Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study |
|
|
| Active, not recruiting | 1 | 9 | US | NYX-783, ((2S, 3R)-3-hydroxy-2-((S)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide), Placebo, Oxycodone | Yale University, National Institute on Drug Abuse (NIDA), Aptinyx | Opioid Use Disorder | 12/24 | 12/24 | | |
NCT04779697: GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight |
|
|
| Active, not recruiting | 1 | 96 | US | GLP-1 analogue - semaglutide, Semaglutide, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Obesity | 01/25 | 06/25 | | |
NCT02616094: Multimodal Neuroimaging of Stress and Reward Cues to Assess Alcoholism Risk and Relapse |
|
|
| Completed | N/A | 224 | US | Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1, Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2 | Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Dependence | 06/22 | 06/22 | | |
NCT04419831: Characterizing Subjective and Physiological Responses to Stress and Pain and Cognitive Learning and Executive Function |
|
|
| Completed | N/A | 81 | US | Yale Stress Pain Test (YSPT) | Yale University | Pain Response, Stress, Trauma | 12/23 | 12/23 | | |
NCT03950453: Preventing Childhood Obesity Through a Mindfulness-Based Parent Stress Intervention |
|
|
| Active, not recruiting | N/A | 246 | US | Parenting Mindfully for Health Nutrition (PMH), Contact Control Nutrition (C+N), Non-randomized historical control (WLC) assessment only, assessment only group | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Child Obesity | 06/23 | 10/24 | | |
| Jastreboff, Ania M |
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity |
|
|
| Recruiting | 3 | 800 | Europe, US, RoW | Retatrutide, LY3437943, Tirzepatide, LY3298176 | Eli Lilly and Company | Obesity | 04/27 | 04/27 | | |
NCT06672939: A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities |
|
|
| Recruiting | 3 | 125 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight | 02/27 | 03/27 | | |
SURPASS-PEDS, NCT05260021 / 2021-003612-31: A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both |
|
|
| Active, not recruiting | 3 | 99 | Europe, US, RoW | Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo | Eli Lilly and Company, Eli Lilly and Company | Type2 Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 2, T2D, T2DM (Type 2 Diabetes Mellitus), Glucose Metabolism Disorders, Endocrine System Diseases, Metabolic Disease | 07/24 | 02/25 | | |
| Not yet recruiting | 3 | 125 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight | 02/27 | 03/27 | | |
| Active, not recruiting | 3 | 2300 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | 04/26 | 05/26 | | |
NCT04779697: GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight |
|
|
| Active, not recruiting | 1 | 96 | US | GLP-1 analogue - semaglutide, Semaglutide, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Obesity | 01/25 | 06/25 | | |
| Angarita, Gustavo A |
NCT05712707: Sublingual Dexmedetomidine for Treating Opioid Withdrawal |
|
|
| Recruiting | 1/2 | 160 | US | BXCL501 (180 micrograms), BXCL501 (240 micrograms), Placebo, Lofexidine (Positive Control) | New York State Psychiatric Institute, BioXcel Therapeutics Inc, Yale University, Clinilabs, Inc., National Institute on Drug Abuse (NIDA), CenExel HRI | Opioid Use Disorder, Opioid Withdrawal | 01/25 | 04/25 | | |
NCT02124941: Glutamate-Glutamine Cycling (VCYC) During Cocaine Abstinence Using 1H-MRS |
|
|
| Completed | 1 | 6 | US | N-acetyl cysteine, [18F]FDG PET scan, 1H MRS, [11C]APP311 PET scan | Yale University, National Institute on Drug Abuse (NIDA) | Cocaine Dependence, Healthy | 08/22 | 08/22 | | |
PHNO, NCT06261905: Vitamin D in OUD: Exploration of Alterations on the Dopamine D2/D3 Receptor System |
|
|
| Recruiting | 1 | 24 | US | [11C]-PHNO, PHNO, Calcitriol, Vitamin D, Placebo Control, PET Scan | Yale University, University of Pennsylvania | Opioid Use Disorder | 07/25 | 07/25 | | |
NCT05447286: Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study |
|
|
| Active, not recruiting | 1 | 9 | US | NYX-783, ((2S, 3R)-3-hydroxy-2-((S)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide), Placebo, Oxycodone | Yale University, National Institute on Drug Abuse (NIDA), Aptinyx | Opioid Use Disorder | 12/24 | 12/24 | | |
NCT06160284: Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) |
|
|
| Not yet recruiting | 1 | 12 | US | Psilocybin | Yale University, National Institute on Drug Abuse (NIDA) | Opioid Use Disorder | 01/27 | 01/27 | | |
| Recruiting | N/A | 80 | US | 11C-UCB-J | Yale University, National Institute on Drug Abuse (NIDA) | Cocaine Use Disorder, Healthy Controls | 06/26 | 06/26 | | |
| Hart, Rachel |
NCT05781009: Pregnenolone for the Treatment of Alcohol Use Disorder |
|
|
| Recruiting | 2 | 150 | US | Pregnenolone, Placebo | Yale University, National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Alcohol Use Disorder | 07/28 | 07/28 | | |
NCT04793685: Prazosin for Alcohol Use Disorder With Withdrawal Symptoms |
|
|
| Recruiting | 1/2 | 150 | US | Prazosin, Minipress, 12-Step Facilitation with Relapse Prevention and Contingency Management | Yale University | Alcohol Withdrawal | 06/26 | 06/27 | | |
NCT04226690: Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products |
|
|
| Completed | 1 | 24 | US | Active CBD/THC Dose 1, Medical marijuana medicine, Active CBD/THC Dose 2, matched placebo comparator, Placebo | Yale University, Connecticut Pharmaceutical Solutions | Pain | 12/23 | 12/23 | | |
NCT03953612: The Role of Neuroactive Steroids in Stress, Drug Craving and Drug Use in Cocaine Use Disorders |
|
|
| Completed | 1 | 58 | US | Pregnenolone (PREG), Placebos | Yale University, National Institute on Drug Abuse (NIDA) | Cocaine-Related Disorders | 05/23 | 05/23 | | |
NCT05447286: Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study |
|
|
| Active, not recruiting | 1 | 9 | US | NYX-783, ((2S, 3R)-3-hydroxy-2-((S)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide), Placebo, Oxycodone | Yale University, National Institute on Drug Abuse (NIDA), Aptinyx | Opioid Use Disorder | 12/24 | 12/24 | | |
| Completed | N/A | 54 | US | Intensive Day Monitoring | Yale University, Peter McManus Charitable Trust | Alcohol Drinking, Alcohol Abuse, Alcohol Use Disorder | 12/23 | 12/23 | | |
NCT04419831: Characterizing Subjective and Physiological Responses to Stress and Pain and Cognitive Learning and Executive Function |
|
|
| Completed | N/A | 81 | US | Yale Stress Pain Test (YSPT) | Yale University | Pain Response, Stress, Trauma | 12/23 | 12/23 | | |
CLR2, NCT05833230: Investigating Real-world Stress-related Mechanisms in Heavy Cannabis Users |
|
|
| Recruiting | N/A | 60 | US | Intensive Day Monitoring | Yale University, Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award | Cannabis Use, Cannabis, Cannabis Abuse | 01/25 | 01/25 | | |
| Hwang, Seungju |
NCT04779697: GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight |
|
|
| Active, not recruiting | 1 | 96 | US | GLP-1 analogue - semaglutide, Semaglutide, Placebo | Yale University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Obesity | 01/25 | 06/25 | | |
| Hermes, Gretchen |
NCT04793685: Prazosin for Alcohol Use Disorder With Withdrawal Symptoms |
|
|
| Recruiting | 1/2 | 150 | US | Prazosin, Minipress, 12-Step Facilitation with Relapse Prevention and Contingency Management | Yale University | Alcohol Withdrawal | 06/26 | 06/27 | | |
| Dauginikas, Emalee |
NCT05447286: Safety, Tolerability and Pharmacokinetics of NYX-783 and Oxycodone DDI Study |
|
|
| Active, not recruiting | 1 | 9 | US | NYX-783, ((2S, 3R)-3-hydroxy-2-((S)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide), Placebo, Oxycodone | Yale University, National Institute on Drug Abuse (NIDA), Aptinyx | Opioid Use Disorder | 12/24 | 12/24 | | |
